🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The largest study on chronic liver disease is projected to early identification of liver injury through screening platform at population level 🧬🔬 Facing the most relevant challenge of a silent disease! #livertwitter LiverAim Università di Torino ihi.europa.eu/news-events/ne…

A gluten-free diet leads to significant improvements in liver and metabolic parameters, as well as patient-reported outcomes in #MASLD. onlinelibrary.wiley.com/doi/10.1111/ap…

Proof-of-concept clinical trial showing that a GLUTEN-free-diet ameliorates MASLD. Is it due to decreased carbs intake and BMI or to immune effects ? Any biomarker for personalized medicine ? #livertwitter roypounder.apt t.ly/BfN1z

Latest #GUTVideo by Angelo Armandi, MD, PhD et al on "Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease" via bit.ly/3VcOPGY Paper: bit.ly/49y90Dd #LiverTwitter #MASLD

Latest #GUTVideo by Angelo Armandi, MD, PhD et al on "Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease" via bit.ly/3VcOPGY Paper: bit.ly/49y90Dd #LiverTwitter #MASLD

Latest #GUTVideo by Angelo Armandi, MD, PhD et al on "Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease" via bit.ly/3VcOPGY Paper: bit.ly/49y90Dd #LiverTwitter #MASLD

🎉Our new Impact Factor is 9.5🎉 👏Many thanks to the Editorial Team, our peer reviewers, and very innovative authors❗️ Jessica Zucman-Rossi EASLnews EASL Education #LiverTwitter

Applications for the #UEGResearch Fellowship 2025 are open! 🙌 UEG will award 2 fellowships to young researchers to conduct a project with a renowned European PI. 📢 We particularly encourage researchers from Inclusiveness Target Countries to apply ➡ bit.ly/3oDfZDO

@lucaswauters3 @melchiorchloe Antonio Molinaro @angeloarmandi André Simão

Non-Invasive CSPH Estimated Risk (NICER) model including Echosens SSM by VCTE at 100Hz 👉Developed (2020-2022) & validated (2023) in contemporary pts. 👉Outperforms ANTICIPATE(-NASH): AUC consistently >0.9. 👉Well-calibrated. 👉Sets a new standard IMHO. #LiverTwitter 🔗👇

Thanks Naim Alkhouri for sharing! Indeed a hot topic, requiring multiple refinements (biomarkers, natural history, trial eligibility and drug targets) - we have just approached a complex but fascinating field!

What’s up in #MASH #treatment⁉️ #ElisabettaBugianesi and Naim Alkhouri presenting 🗣️#novel 💊➕💉 and response Myself added 👨‍💻📈 #NIT to treatment from #resmetirom and #semaglutide my_UEG Rohit Loomba Manal Abdelmalek Elliot Tapper Mazen Noureddin, MD, MHSc Phil Newsome Quentin M. Anstee 🪑@HannesHagstrom

Are you a young researcher looking to grow your skills? The #UEGResearch Fellowship offers 12 months at a top European institution to work on a basic or clinical project. 🌍🔬 📅 Apply by Dec 4, 2024! Need a host institution? We’ve got you covered ➡️ bit.ly/3oDfZDO

Our latest review on the impact of #PNPLA3 variants on clinical outcomes in #MASLD is out in Liver International open access Salvatore Petta Luca Valenti Stefano Romeo onlinelibrary.wiley.com/doi/full/10.11…

Lucas Wauters Antonio Molinaro Michał Żorniak Angelo Armandi, MD, PhD André Simão

Fibrosing MASH (F2-F3) and MASH-cirrhosis/ACLD are clinically relevant entities requiring both liver-targeted and systemic/metabolic management. In the diabetic population, GLP1-RAs should be preferred for their beneficial impact on liver histology, and safety in Child A

What’s the best way to implement the 2-step clinical care pathway for evaluating MASLD? Is it as effective as VCTE for all patients? Check out this paper in J Hep: authors.elsevier.com/sd/article/S01…. Congrats to Terry Cheuk-Fung Yip and the VCTE-Prognosis Study Team! 🎉 #MASLD #ClinicalResearch

🚀#LIVERAIM is on the move! Biomarker analysis for early liver fibrosis detection has started at #CORELAB of Hospital Clínic on 22k+ serum samples from general and high-risk populations. 🔎Watch how science is shaping the future! #livertwitter Innovative Health Initiative IDIBAPS EASLnews

❓Did you miss the second #LIVERAIM webinar? Check out our Youtube channel and discover what an #earlydiagnosis of #chronicliverdisease truly means for patients! 🎥youtube.com/watch?v=jmw5jp… #LiverTwitter

#LIVERAIM networking session is starting at track hub8! Join us and learn from Jörn Schattenberg and ELISA POSE how #biomarkers of #liverfibrosis can reshapethe future of Hepatology #livertwitter #EASLCongress Innovative Health Initiative EASL Education EASLnews Aleksander Krag Jeffrey V. Lazarus Maja Thiele